Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 8
Submit an article Journal homepage
164
Views
30
CrossRef citations to date
0
Altmetric
Short Communication

Subdural Hematomas during CML Therapy with Imatinib Mesylate

KW Song Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
,
J Rifkind Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
B Al-Beirouti Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
K Yee Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
J McCrae Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
HA Messner Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
A Keating Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
&
JH Lipton Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
 show all
Pages 1633-1636 | Received 03 Aug 2003, Published online: 26 Aug 2009

References

  • Sawyers, C.L. (1999) "Medical Progress: Chronic Myeloid Leuke-mia", New England Journal of Medicine, 340, 1330— 1340.
  • Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., et al. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", New England Journal of Medicine, 346, 645–652.
  • Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood, 99, 1928 — 1937.
  • Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., et al., (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine lcinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", New England Journal of Medicine, 344, 1038 — 1042.
  • Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine lcinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031 — 1037.
  • Ebnether, M., Stentoft, J., Ford, J., Buhl, L. and Gratwohl, A. (2002) "Cerebral oedema as a possible complication of treatment with imatinib [letter]", Lancet, 359, 1751–1752.
  • Elliott, M.A., Mesa, R.A., Tefferi, A., Burton, C., Azzi, A. and Kerridge, I. (2002) "Adverse events after imatinib mesylate therapy", New England Journal of Medicine, 346, 712–713.
  • Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, 0.G., et al. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood, 99, 3530–3539.
  • Kantarjian, H.M., Dixon, D., Keating, M.J., Talpaz, M., Walters, R.S., McCredie, KB., et al. (1988) "Characteristics of accelerated disease in chronic myelogenous leukemia", Cancer, 61, 1441 — 1446.
  • Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M. and Goldman, J.M. (2001) "Chronic myelogenous leukemia", Hematology (American Society of Hematology Educational Pro-gram), 87 — 112.
  • Yamauchi, K. and Umeda, Y. (1997) "Symptomatic intracranial haemorrhage in acute nonlymphoblastic leukaemia: analysis of CT and autopsy findings", Journal of Neurology, 244, 94 — 100.
  • Chen, J.C. and Levy, M.L. (2000) "Causes, epidemiology, and risk factors of chronic subdural hematoma". Neurosurgery Clinics of North America, 11, 399–406.
  • Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., et al. (2002) "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stomal tumors", NEJM, 347, 473–480.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.